Therapy targets leukemia stem cells

New research takes aim at stubborn cancer stem cells that are thought to be responsible for treatment resistance and relapse. The study, published by Cell Press in the February 14 issue of the journal Cancer Cell, provides insight into mechanisms associated with the survival of leukemia stem cells and identifies a potential therapeutic target that is specific for these dangerously persistent cells.

Chronic myelogenous leukemia (CML) is a cancer of the for which are currently the first line of therapy. These drugs prolong survival, but is often seen after drug treatment is stopped. "Tyrosine kinase inhibitors do not eliminate leukemia stem cells, which remain a potential source of ," explains senior coauthor Dr. Ravi Bhatia from the City of Hope National Medical Center in Duarte, California. "CML patients need to take tyrosine kinase inhibitor treatment indefinitely, which carries a significant risk of toxicity, lack of compliance, drug resistance, relapse, and associated expense."

Strategies targeting leukemia stem cells are necessary to achieve a cure. Previous work has implicated the enzyme sirtuin 1 (SIRT1) in protecting stem cells from stress and in playing a role in leukemia, as well as other types of cancer. In the current study, Dr. Bhatia, coauthor Dr. WenYong Chen, first author Ling Li, and their colleagues investigated whether SIRT1 was involved in the survival and growth of CML stem cells. The researchers discovered that SIRT1 was overexpressed in CML stem cells and that inhibition of SIRT1selectively reduced the survival and growth of CML stem cells. Importantly, SIRT1 inhibition was associated with activation of the .

Taken together, the results reveal a specific mechanism that supports the survival of leukemia stem cells. "Our findings are important because they show that SIRT1-mediated inactivation of p53 contributes to CML leukemia stem cell survival and resistance to treatment with tyrosine kinase inhibitors," concludes Dr. Chen. "We suggest that SIRT1 inhibition is an attractive approach to selectively target leukemia stem cells that resist elimination by current treatments."

add to favorites email to friend print save as pdf

Related Stories

Combination therapy targets stubborn leukemia stem cells

May 17, 2010

New research discovers a combination of drugs that may prove to be a more effective treatment for a lethal form of leukemia. The study, published by Cell Press in the May issue of the journal Cancer Cell, reports that the ne ...

New approach to leukemia chemotherapy -- is a cure in sight?

Mar 31, 2011

Speaking at the UK National Stem Cell Network conference in York later today (31 March), Professor Tessa Holyoake from the University of Glasgow will discuss a brand new approach to treating chronic myeloid leukaemia (CML) ...

Fish oil may hold key to leukemia cure

Dec 22, 2011

A compound produced from fish oil that appears to target leukemia stem cells could lead to a cure for the disease, according to Penn State researchers. The compound -- delta-12-protaglandin J3, or D12-PGJ3 ...

Recommended for you

Discovery could lead to new cancer treatment

11 hours ago

A team of scientists from the University of Colorado School of Medicine has reported the breakthrough discovery of a process to expand production of stem cells used to treat cancer patients. These findings could have implications ...

Is the HPV vaccine necessary?

18 hours ago

As the school year starts in full swing many parents wonder if their child should receive the HPV vaccine, which is recommended for girls ages 11-26 and boys 11-21. There are a lot of questions and controversy around this ...

User comments